After this transaction With the target company to ensure the target company’s market competitiveness and long-term
stable development capabilities. However, if there are adverse changes in the target company’s future
operating activities, the goodwill will be at risk of impairment and will have an adverse impact on the company’s future current profit and loss.
Dai Lizhong, Chairman of Shengxiang Bio, said that saint helena email list 100000 contact leads efficient integration and personalization of
prevention, diagnosis and treatment is the inevitable trend of proactive health, and is also the direction
of Shengxiang Bio’s innovation and exploration in the new era of life science.
The strong alliance between Shengxiang Bio and Zhongshan
Haiji will leverage the resource advantages of precision diagnosis and biomanufacturing, which will help
create an integrated health solution for pediatric diagnosis and treatment.
Performance has declined for three consecutive years
Before this merger and acquisition , Shengxiang Bio ‘s attributable net profit had declined for three
consecutive years from 2021 to 2023 .
Data shows that from 2020 to 2023, Shengxiang build a training and development program Bio achieved revenues of 4.763 billion yuan, 4.515
billion yuan, 6.45 billion yuan and 1.007 billion yuan, respectively; among which the full-year
operating income in 2023 showed a sharp decline; from 2020 to 2023, the company ‘s attributable net
profits were 2.617 billion yuan, 2.243 billion yuan, 1.937 billion yuan and 364 million yuan, respectively.
In the first three quarters of 2024, Shengxiang Bio’s attributable net profit also declined
During the reporting period, the company achieved operating income of 1.033 billion yuan, a year-on-
year increase of 63.24%; the corresponding attributable net profit was 195 million yuan, a year-on-year decrease of 34.8%.
In order to reduce its dependence on the sales liechtenstein number of new coronavirus nucleic acid testing reagents and
instruments , in 2022, Shengxiang Bio proposed “second entrepreneurship” to find new growth points.
On May 9, 2023, the company announced that it plans to jointly invest with its related parties to establish Hunan Shengxiang Ansai Biotechnology Co., Ltd. to further improve the company’s comprehensive strategic layout in the field of immunodiagnosis, especially chemiluminescence After this transaction.